Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial

British Journal of Haematology ◽

10.1111/bjh.15248 ◽

2018 ◽

Vol 181 (5) ◽

pp. 628-636 ◽

Cited By ~ 4

Author(s):

Paul G. Richardson ◽

Robert L. Schlossman ◽

Anuja N. Roy ◽

Ashok Panneerselvam ◽

Suddhasatta Acharyya ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.95 ◽

2017 ◽

Vol 1 ◽

pp. s96

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract Not AvailableDisclosure: Study supported by Dermira.

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.2.supp.41 ◽

2018 ◽

Vol 2 ◽

pp. S41

Author(s):

David M Pariser ◽

Adelaide A Hebert ◽

Janice Drew ◽

John Quiring ◽

Dee Anna Glaser

Keyword(s):

Axillary Hyperhidrosis ◽

Phase 3 ◽

Double Blind ◽

Abstract not available. Disclosures: Study supported by Dermira. Copyright SKIN 2018

Patient‐Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis Care & Research ◽

10.1002/acr.22044 ◽

2013 ◽

Vol 65 (10) ◽

pp. 1666-1673 ◽

Cited By ~ 16

Author(s):

Arthur Kavanaugh ◽

Iain B. McInnes ◽

Gerald G. Krueger ◽

Dafna Gladman ◽

Anna Beutler ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Clinical Response ◽

Controlled Trial ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.12081 ◽

2013 ◽

Vol 28 (2) ◽

pp. 192-203 ◽

Cited By ~ 38

Author(s):

C. Mamolo ◽

J. Harness ◽

H. Tan ◽

A. Menter

Keyword(s):

Kinase Inhibitor ◽

Severe Psoriasis ◽

Janus Kinase ◽

Controlled Study ◽

Double Blind ◽

Janus Kinase Inhibitor ◽

Double Blind Placebo ◽

Patient-reported outcomes in subjects receiving botulinum toxin type A (BoNTA) treatment for moderate to severe glabellar rhytids: Results from two randomized, double-blind, placebo-controlled studies

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2006.10.897 ◽

2007 ◽

Vol 56 (2) ◽

pp. AB197

Keyword(s):

Botulinum Toxin ◽

Botulinum Toxin Type A ◽

Type A ◽

Botulinum Toxin Type ◽

Double Blind ◽

Double Blind Placebo ◽

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30898-2 ◽

2019 ◽

Vol 20 (4) ◽

pp. 556-569 ◽

Cited By ~ 30

Author(s):

Bertrand Tombal ◽

Fred Saad ◽

David Penson ◽

Maha Hussain ◽

Cora N Sternberg ◽

...

Keyword(s):

Prostate Cancer ◽

Castration Resistant Prostate Cancer ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Patient-Reported Outcomes (PROs) From the Phase 3 A.R.R.O.W. Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2018.07.130 ◽

2018 ◽

Vol 18 ◽

pp. S240 ◽

Cited By ~ 1

Author(s):

Philippe Moreau ◽

Shaji Kumar ◽

Ralph Boccia ◽

Shinsuke Iida ◽

Hartmut Goldschmidt ◽

...

Keyword(s):

Multiple Myeloma ◽

Phase 3 ◽

Refractory Multiple Myeloma ◽

Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study

Value in Health ◽

10.1016/j.jval.2013.03.1150 ◽

2013 ◽

Vol 16 (3) ◽

pp. A227 ◽

Cited By ~ 2

Author(s):

J. Sieper ◽

A. Kivitz ◽

A. van Tubergen ◽

A. Deodhar ◽

G. Coteur ◽

...

Keyword(s):

Ankylosing Spondylitis ◽

Axial Spondyloarthritis ◽

Certolizumab Pegol ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Psychometric Evaluation of Patient-Reported Outcome Measures for Assessing IBS-C Symptom Severity and Change: Results From 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials of Linaclotide

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-01479 ◽

2012 ◽

Vol 107 ◽

pp. S590-S591

Author(s):

Robyn Carson ◽

Lauren Nelson ◽

Valerie Williams ◽

Sheri Fehnel ◽

Stavros Tourkodimitris ◽

...

Keyword(s):

Outcome Measures ◽

Symptom Severity ◽

Psychometric Evaluation ◽

Patient Reported Outcome Measures ◽

Patient Reported Outcome ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽